Видео ютуба по тегу Oral Serd

Dialing Up Precision in HR+, HER2 MBC With New Therapies
Dialing Up Precision in HR+, HER2 MBC With New Therapies
lidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancer
lidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancer
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Trending in Women’s Health: IBD in pregnancy, SERD win and more
Trending in Women’s Health: IBD in pregnancy, SERD win and more
Trending in Women’s Health: IBD in pregnancy, SERD win and more
Trending in Women’s Health: IBD in pregnancy, SERD win and more
Trending in Women’s Health: IBD in pregnancy, SERD win and more
Trending in Women’s Health: IBD in pregnancy, SERD win and more
Women’s Health Update – November 26, 2025: IBD Pregnancy Guidance, Oral SERD Win and More
Women’s Health Update – November 26, 2025: IBD Pregnancy Guidance, Oral SERD Win and More
Role of Oral SERDs in the Care of Patients with ER-Positive Metastatic Breast Cancer
Role of Oral SERDs in the Care of Patients with ER-Positive Metastatic Breast Cancer
New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer
New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer
Advanced HR-Positive Breast Cancer: Oral SERDs in Focus
Advanced HR-Positive Breast Cancer: Oral SERDs in Focus
Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 7
Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 7
Пероральные SERD-препараты: новый вариант лечения для пациенток с раком молочной железы.
Пероральные SERD-препараты: новый вариант лечения для пациенток с раком молочной железы.
Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond
Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond
The landscape of oral SERDs and their potential in ER+ breast cancer
The landscape of oral SERDs and their potential in ER+ breast cancer
SABCS 2021: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s...
SABCS 2021: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s...
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC